required higher concentrations (84.33% at 75% MBC). These results demonstrated that marine bacterial metabolites produce biocompatible Se-Cu BMNPs with potent antioxidant, anti-inflammatory, antimicrobial, and antibiofilm properties suitable for biomedical applications.
The Eucalyptus globulus essential oil (EGEO) is widely recognized for its pharmacological relevance; however, comprehensive evaluation of its phytochemical composition and bioactivities remains limited. In this study, EGEO was extracted from fresh leaves via hydro-distillation and characterized using GC-MS, LCMS, FTIR, and UV-Visible spectroscopy. Qualitative screening confirmed the presence of key secondary metabolites, including triterpenoids, flavonoids, phenols, steroids. Quantitative analysis revealed high levels of total phenolics (65.12 ± 0.01 mg GAE/g) and flavonoids (57.75 ± 0.01 mg QE/g). The oil exhibited concentration-dependent antioxidant activity in the DPPH assay with an IC₅₀ value of 604.01 µl/mL, indicating potent radical-scavenging ability. Anti-inflammatory assessment through protein denaturation and human red blood cell (HRBC) membrane stabilization assays demonstrated moderate inhibitory and cytoprotective effects comparable to standard drugs. EGEO also showed strong antibacterial efficacy against Tannerella forsythia, Prevotella intermedia and Aggregatibacter with inhibition zones of 19-25 mm while showed notable antibiofilm activity against T. forsythia. Cytotoxic evaluation indicated selective action, showing minimal toxicity toward normal L929 fibroblasts and moderate inhibition of B16F10 melanoma cells. Overall, these findings suggest that Eucalyptus globulus essential oil is a rich source of bioactive phytoconstituents with potential therapeutic applications as a natural antioxidant, anti-inflammatory, antibacterial, antibiofilm, and anticancer agent.
The advent of CRISPR‒Cas technology has revolutionized genome editing by providing unprecedented precision, efficiency, and versatility in genetic manipulation. This revolutionary system originated from bacterial adaptive immunity. It allows the programmed modification of DNA sequences in a highly specific way, as long as the desired modification site contains an enzyme-compatible protospacer adjacent motif (PAM) sequence. Recent innovations with CRISPR‒Cas systems have focused on optimizing delivery methods, addressing challenges and expanding their therapeutic applications. Delivery approaches, including viral vectors, lipid nanoparticles, and other nonviral vectors, have been improved to increase target specificity while minimizing off-target effects, ensuring safe and efficient In Vivo genome editing. The applications of CRISPR‒Cas technology include the correction of genetic disorders, engineering of immune cells for cancer therapy, and combating viral infections. However, significant challenges in the form of unintended edits, immune responses, and delivery to specific tissues or organs remain formidable barriers to clinical translation. New CRISPR variants, such as base editing, prime editing, and epigenome editing, provide solutions to improve accuracy and broaden intervention. This review covers recent progress in various CRISPR delivery methodologies, discusses broadening therapeutic applications, highlights ongoing challenges, and describes the future trajectory of this disruptive technology.
Frontiers in Microbiology · مجلد 17 · 1881796-1881796
Helicobacter pylori is one of the most prevalent pathogenic microorganisms worldwide. The treatment of H. pylori infections is challenging due to the increasing antibiotic resistance. Therefore, alternative therapies are crucial for addressing these issues. This study aimed to investigate alternative approaches to combat H. pylori infection using lactic acid bacteria. Nineteen LAB isolates exhibited strong tolerance to simulated gastric acid and bile salts, as well as notable auto-aggregation and co-aggregation capabilities. Among them, isolates L20, L22, and L40 showed superior performance. Their neutralized cell-free supernatants (n-CFSs) significantly inhibited H. pylori urease production by 69, 66, and 67%, respectively, and reduced biofilm formation by 88, 82, and 80%, respectively. Molecular identification revealed that isolates L20 and L40 belonged to Lactiplantibacillus plantarum , while L22 was identified as Limosilactobacillus fermentum . Furthermore, the n-CFS of L. plantarum L20 markedly downregulated the expression of H. pylori virulence genes, including vacA , cagA , ureA , and babA, with fold reductions of 79, 68, 90, and 96%, respectively. In vivo , treatment with L. plantarum L20 n-CFS resulted in 1.28 log reduction in H. pylori colonization ( p < 0.001). Proteomic analysis further identified metabolically active proteins associated with catalytic and secondary metabolite pathways, supporting their mechanistic role in anti- H. pylori activity. These findings highlight the potential of LAB-derived n-CFS, particularly L. plantarum L20, as a promising antivirulent strategy against H. pylori infections.
International Journal of Clinical Pediatric Dentistry · مجلد 19 (6) · 779-793
Background: Dental caries is a common oral health problem that affects people all over the world. To detect and treat it early on, it is important to have a thorough understanding of its genesis and potential biomarkers. Objective: The objective of this systematic review is to answer the question: "Is there any role of immune status in the development of dental caries among children and adults, and is there any potential in using immunological markers for diagnosis, prognosis, and treatment of this condition?" Design: From 2016 to 2024, a thorough search approach adhering to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria was used across several datasets (PROSPERO: CRD42024612045). To find pertinent publications, a total of 2,723 articles were searched using keywords associated with dental caries, immunity, and interventions. The inclusion criteria included papers that addressed the connection between immunity and the development of caries, interventions, and results, including alterations in basal metabolic rate (BMR), weight gain in patients, improvements in quality of life, and recurrence of carious lesions. Two reviewers independently extracted the data, assessed its quality, and assessed the risk of bias using validated instruments such as the Cochrane Risk of Bias tool and the Newcastle-Ottawa Scale. Results: The evaluation encompassed 10 articles in all, demonstrating noteworthy correlations between immunological indicators and dental caries. Results point to a favorable correlation between salivary immunoglobulin A (IgA) levels and the number of carious teeth, as well as an increase in proinflammatory cytokine concentrations in dental caries patients. Furthermore, the pulp tissue of dental caries patients has different bacterial communities and higher expression of proinflammatory cytokines, suggesting a possible connection between immune activation and dysbiosis. Conclusion: The findings highlight the significance of immune status/immunological indicators in the diagnosis and treatment of dental caries, emphasizing the necessity for additional study to corroborate these conclusions and improve treatment and preventative dental care practices. Clinical relevance: This work has got great relevance to pediatric dentists. The current work highlights a possible link between the immune status and the development of caries in pediatric and adult patients as well as the potential of immunological markers in the diagnosis, prognosis, and treatment of dental caries in both pediatric and adult patients. Prospero registration number: CRD42024612045.
ABSTRACT Juniperus phoenicea ssp. Turbinata L. ( J. phoenicea ssp. Turbinata) has long been used in traditional medicine to treat a variety of ailments. This study aimed to investigate the pharmacological potential and to characterize the phytochemical composition of the hydroethanolic leaf (JPEF) and fruit (JPEG) extracts. Liquid Chromatography Tandem Mass Spectrometry (LC–MS/MS) analysis revealed that both JPEF and JPEG contained high levels of phenolic compounds, with ferulic acid identified as the dominant constituent. The biological evaluation began with acute toxicity tests in rodents, which indicated that JPEF and JPEG extracts were well tolerated at the doses administered, with no significant adverse effects observed. The extracts exhibited strong anti‐inflammatory activity (94.23% for JPEF; 83.24% for JPEG), comparable to that of diclofenac (97.02%), as well as a notable analgesic effect (75% and 70.62%), compared to tramadol (87.01%). Significant antioxidant activity was observed (DPPH IC 50 : 70.2 and 90.76 μg/mL), accompanied by antimicrobial activity (bacterial inhibition zones: 11.44–20.36 mm; fungal: 13.59–20.38 mm). Molecular docking revealed a stable interaction between the compounds and several enzymatic targets. These results confirm the potential of J. phoenicea ssp. turbinata as a promising source of therapeutic agents.
Globally, environmental pollution caused by resilient protein like collagen is escalating due to inefficient disposal practices. Accumulation of collagen waste poses ecological threat, necessitating management strategies. Current study discloses collagenolytic bacterium, Bacillus siamensis strain Z1, isolated from marine water (Goa) demonstrating collagen breakdown and inducing collagenase biosynthesis. Production kinetics revealed optimal collagenase production (4.55 U/mL) on 2nd day with a protein content of 0.69 mg/mL. Influence of physiochemical parameters, including inoculum size, metal ions, carbon and nitrogen sources, pH and temperature on collagenase yield was optimized achieving 17.93 folds enhancement by central composite design. Silver (AgNP) and Zinc oxide (ZnONP) nanoparticles were biosynthesized using collagen hydrolysate derived from marine collagen through collagenase action and characterized using UV-Visible spectroscopy, Fourier Transform Infrared Spectroscopy, X-ray Diffraction, Scanning Electron Microscopy with Energy Dispersive X-ray, Thermogravimetric Analysis and Atomic Force Microscopy elucidated thermostability, structure and surface characteristics. Antibacterial effect of nanoparticles was observed against B. cereus and E. coli. AgNP and ZnONP demonstrated antioxidant properties assessed by ABTS and DPPH assays. AgNP and ZnONP exhibited cytotoxicity on MCF-7 breast cancer cell lines, with IC50 values 8.87 µg/mL and 25.21 µg/mL respectively. The study highlights biotechnological potential of collagenase in generating bioactive products for therapeutical and biomedical advancements.
Background Chronic obstructive pulmonary disease (COPD) with exacerbations often triggered by infections. Bacterial lysates have been investigated as interventions to reduce the exacerbations of COPD. Methods We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) evaluating bacterial lysates (BLs) in adults with chronic obstructive pulmonary disease (COPD). PubMed, EMBASE, CENTRAL, Web of Science, Google Scholar, ICTRP, and ClinicalTrials.gov were searched. In adults with COPD that compared bacterial lysates with placebo or conventional COPD therapy. Primary outcomes were the effect of BLs on exacerbations and duration. Secondary outcomes were hospitalisation risk, the mean number of exacerbations per participant during trial follow up, symptom scores for dyspnoea, sputum, cough, and adverse events. We used random-effects meta-analysis, assessed risk of bias with Cochrane RoB 2, graded certainty with GRADE. Results Fifteen RCTs were included. The pooled risk ratio (RR) for exacerbation in patients with COPD treated with BLs vs. control was 0.83 (95% CI 0.74–0.93; P = 0.0009). The mean difference (MD) for exacerbation duration showed no statistical significant reduction −9.26 Days (95% CI −19.56 to 1.03; P = 0.08). Mean number of exacerbations (MD) −0.19 (95% CI −0.30 to −0.08; P = 0.0009). Hospitalisation RR was 0.52 (95% CI 0.35–0.78; P = 0.001).Symptom outcomes were dyspnoea standardised mean difference (SMD) −0.42 (95% CI −0.75 to −0.10; P = 0.01), cough (SMD) −0.37 (95% CI −0.63 to −0.11; P = 0.006), while sputum production showed no significant change (SMD) −0.20 (95% CI −0.65 to 0.25; P = 0.39), The RR for adverse events was 0.95 (95% CI 0.86–1.04; P = 0.27). Conclusion Bacterial lysates may be associated with lower COPD exacerbation and hospitalisation risk, with small numerical improvements in dyspnoea, cough, sputum production showed no significant improvement; effects varied by formulation, these findings require confirmation in formulation specific trials. Systematic Review registration https://www.crd.york.ac.uk/PROSPERO/view/CRD42024570783 , PROSPERO CRD42024570783.
Protracted bacterial bronchitis (PBB) is a treatable cause of chronic wet cough in children but is frequently missed.Unrecognized children often cycle through repeat asthma treatment, short antibiotic courses that do not address the infection, or open-ended reassurance without further evaluation.This review summarizes the clinical presentation, diagnostic criteria, differential diagnosis, treatment, and follow-up of PBB in children.We conducted a targeted narrative review (PubMed, through September 2026) of clinical trials, longitudinal studies, systematic reviews, and professional-society guidance, distinguishing evidence for antibiotic treatment from limited observational evidence linking recurrent PBB to bronchiectasis.Clinicians should suspect PBB in a child with a daily wet cough lasting more than four weeks and no findings indicating another cause.Resolution after an appropriate antibiotic course supports the diagnosis.Amoxicillinclavulanate remains the usual first-line treatment, typically for two weeks initially, with reassessment and selective extension to four weeks if the child has not cleared.Further investigation is warranted when symptoms persist despite adequate treatment, recurrence is frequent, or specific warning signs appear.In an otherwise typical, treatment-responsive case, bronchoscopy and chest computed tomography (CT) are not routine first steps.Management hinges on recognizing the wet-cough phenotype, giving an adequate therapeutic trial, confirming resolution, and investigating promptly when treatment fails.Antibiotics appear to improve cough resolution, but this rests on a small number of trials with limited certainty, and evidence that treatment itself prevents bronchiectasis remains thin.
Libyan Journal of Medicine · مجلد 21 (1) · 2746284-2746284
This study reports the biosynthesis of a Selenium/Zinc nanocomposite (Se/Zn NC) using a marine bacterial extract from Bacillus rugosus SYG20. FT-IR detected Zn–O stretching vibrations at 614.81, 500.71, and 463.61 cm⁻¹, together with shifts in biomolecule peaks. XRD revealed a hexagonal wurtzite structure with an average crystallite size of 14.9 nm, and UV–Vis spectroscopy gave an optical band gap of 3.46 eV. TEM showed spherical particles of 10–80 nm, while HRTEM lattice fringes and a polycrystalline diffraction pattern matching cubic ZnSe planes confirmed strong interfacial Se–Zn coordination. DLS indicated a hydrodynamic diameter of 87 nm with a polydispersity index of 0.28. EDX confirmed Se incorporation at 7.0 wt% (Zn:Se atomic ratio ≈ 1.6:1). XPS showed Zn in the divalent state and Se bound to the metal centers rather than as elemental selenium, with a Zn 2p binding-energy shift indicating interfacial coordination rather than a native oxide layer. Hemolysis remained below 1.5% even at 1000 μg/mL, and cytotoxicity against WI-38 normal fibroblasts showed a wide safety margin (IC₅₀ = 392.64 ± 4 μg/mL). The nanocomposite exhibited strong antioxidant activity, with IC₅₀ values of 11.85 ± 0.11 μg/mL (DPPH) and 11.46 ± 0.05 μg/mL (ABTS⁺•), reaching 94.4% and 93.9% inhibition, respectively. Anti-inflammatory assays gave IC₅₀ values of 6.67 ± 0.5 μg/mL for COX-1 and 14.12 ± 0.1 μg/mL for COX-2. Protein denaturation was inhibited with an IC₅₀ of 2.04 ± 0.05 μg/mL, nearly matching diclofenac sodium (2.01 ± 0.04 μg/mL). Antidiabetic screening showed α-amylase and α-glucosidase inhibition with IC₅₀ values of 5.24 and 7.84 μg/mL, and 95.4% and 95.7% blockade at 1000 μg/mL. These in vitro findings support the potential of B. rugosus-derived Se/Zn NC against oxidative stress-related metabolic disorders.
ABSTRACT Isatin‐based ligands have been recognized for their remarkable pharmacological potential and this study reports the synthesis, characterization, and biological evaluation of three novel nickel(II)‐isatin hydrazone complexes ( C1–C3 ). The complexes were characterized by FT‐IR, UV–vis, mass spectroscopy, DFT, magnetic, conductivity and thermal analyses indicating octahedral geometry and appreciable heat stability. Molecular electrostatic potential mapping gave information on their electronic properties. DFT calculations indicated decreased HOMO–LUMO gaps indicating increased reactivity. Biological screening showed remarkable anticancer activity against HCT‐116, A549, MCF‐7, and HepG‐2 cell lines (IC 50 = 7.22–17.33 µM), potent antibacterial and antifungal activities comparable to ciprofloxacin and clotrimazole against Staphylococcus aureus and Candida albicans , and significant antioxidant activity with 59%–69% of the radical scavenging. Molecular docking and dynamics studies showed the stable binding interactions with the target enzyme FabH especially for complex C3 . These results collectively highlight C1‐C3 as multifunctional therapeutic candidates with stability and reactivity properties, making them attractive scaffolds for pharmacological development.
Rifaximin, a minimally absorbed broad-spectrum oral antibiotic, is used to target gut dysbiosis in patients with irritable bowel syndrome (IBS).However, conflicting trial data and methodological heterogeneity necessitate an updated, rigorous synthesis of its efficacy and safety profile.We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing rifaximin with placebo in adult patients with IBS, adhering to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 guidelines.The primary outcome was global symptom relief at the end of the treatment.Data were pooled using inverse-variance random-effects models with Hartung-Knapp-Sidik-Jonkman (HKSJ) adjustment.Evidence robustness was evaluated using prediction intervals (PI), Trial Sequential Analysis (TSA), trim-and-fill algorithms for publication bias, and the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology.Nine RCTs (yielding 10 randomized comparisons due to one trial's a priori stratification by small intestinal bacterial overgrowth status) were included in this review.For the primary outcome (eight comparisons, N=2,056), rifaximin significantly improved global symptom relief compared to placebo (RR 1.54, 95% CI 1.13 to 2.11; p=0.014), corresponding to a number needed to treat for benefit (NNTB) of 6.However, statistical heterogeneity was substantial (I 2 =59.5%), and the 95% PI crossed the line of no effect (0.89-2.67).The primary effect lost statistical significance upon the exclusion of high-risk-of-bias trials (RR 1.47, 95% CI 0.95-2.27)and after adjusting for publication bias using the trim-and-fill method (RR 1.37, 95% CI 0.93-2.01).The TSA indicated that the accrued information size remained inconclusive for a conservative 15% relative benefit.Rifaximin demonstrated no statistically detectable difference in adverse events compared to placebo, though this is accompanied by considerable uncertainty (Peto OR 0.89 (95% CI 0.65-1.22)).Rifaximin demonstrates a modest overall benefit for global IBS symptoms and an excellent safety profile; however, the certainty of evidence is very low.The apparent efficacy is highly fragile, driven largely by industry-funded trials, undermined by publication bias, and characterized by wide prediction intervals.Biomarker-guided stratification, such as testing for small intestinal bacterial overgrowth (SIBO), may be required to optimize patient selection in future independent trials.
Journal of Clinical Medicine · مجلد 15 (18) · 7071-7071
Background/Objectives: To systematically evaluate and compare the clinical efficacy and safety of non-cryotherapy modalities versus standard liquid nitrogen cryotherapy for the treatment of plantar warts, while exploring the influence of specific cryotherapy procedural parameters and intervention-related subgroup characteristics on treatment outcomes. Methods: A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted according to PRISMA guidelines. We searched four major databases from inception until 1 July 2026. The primary outcome was complete clearance. Secondary outcomes included partial clearance, recurrence, and treatment-related adverse events. Pooled risk ratios (RR) with 95% confidence intervals (CI) were calculated using random-effects models. Results: Thirty-one RCTs involving 2313 patients were included. No statistically significant difference was detected between non-cryotherapy modalities and cryotherapy in complete clearance rates (RR = 1.09, 95% CI: 0.98–1.20; p = 0.10; I2 = 0.00%) or recurrence outcomes (RR = 0.90, 95% CI: 0.56–1.44; p = 0.66). Partial clearance significantly favored cryotherapy (RR = 0.65, 95% CI: 0.44–0.95; p = 0.03), particularly in subgroup analyses using two freeze–thaw cycles and treatment intervals of every two weeks. Regarding safety, topical therapies demonstrated significantly lower erythema rates than cryotherapy, while no statistically significant differences were observed in blistering, scarring, or secondary bacterial infection. Conclusions: No statistically significant difference was detected between non-cryotherapy modalities and cryotherapy regarding complete clearance or recurrence of plantar warts. Cryotherapy may offer better partial clearance under optimized treatment parameters, whereas topical therapies may be better tolerated in selected patients.